Want to see XENE full AI Analyst Report?
XENE Stock Chart & Stats
$65.42
$0.00(0.00%)
At close: 4:00 PM EDT
$65.42
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$30.65 - $72.66
Previous CloseN/A
Volume529.96K
Average Volume (3M)1.58M
Market Cap
$6.06B
Enterprise Value$3.99K
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$7.49M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 06, 2026EPS Estimate
-1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.70
Shares Outstanding96,665,550
10 Day Avg. Volume933,915
30 Day Avg. Volume1,582,546
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)6.11
Price to Sales (P/S)473.62
P/FCF Ratio-12.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$75.88Price Target Upside15.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-4.75
Revenue Forecast (FY)$2.34M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & RunwayA liquid balance sheet with ~$1.3B and very low leverage materially reduces near‑term solvency risk and supports late‑stage programs and initial commercial buildout. This funding runway allows multi‑year investment in launch planning, payer engagement and parallel Phase 3 programs without immediate dilution.
Robust Phase 3 Efficacy And DurabilityClear, large Phase 3 efficacy and durable open‑label extension seizure‑freedom signals provide clinical differentiation versus existing ASMs. Strong responder rates and 800+ patient‑years safety exposure raise the odds of label strength, prescriber adoption, and favorable payer consideration after approval.
Defined Regulatory & Commercial TimelineA specified NDA timetable and planned FDA interactions materially reduce milestone uncertainty versus many peers. Clear regulatory milestones enable focused resource allocation for commercialization, payer discussions and manufacturing scale‑up, improving likelihood of coordinated market entry if timelines hold.
Bears Say
Sustained High Cash BurnMaterial negative operating and free cash flows imply persistent funding needs beyond routine operations. Even with current cash, continued high burn leaves the company vulnerable to timeline slips or unexpected costs, increasing the probability of future financing and dilution if revenues or approvals are delayed.
Pre‑commercial Profile And Widening LossesZero or minimal revenue combined with widening net losses means the company lacks operational cash generation to absorb setbacks. Commercial success is binary for revenue realization; absent approval and adoption, continued losses will pressure resources and limit strategic optionality over the medium term.
Commercial And Payer Execution RiskTransitioning from development to commercial execution is a distinct competency. Payer coverage, formulary placement, physician adoption and field effectiveness determine real market uptake. Failure to secure coverage or execute the launch would prolong losses and necessitate additional capital or strategic pivots.
Xenon News
XENE FAQ
What was Xenon Pharmaceuticals’s price range in the past 12 months?
Xenon Pharmaceuticals lowest stock price was $30.65 and its highest was $72.66 in the past 12 months.
What is Xenon Pharmaceuticals’s market cap?
Xenon Pharmaceuticals’s market cap is $6.06B.
When is Xenon Pharmaceuticals’s upcoming earnings report date?
Xenon Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Xenon Pharmaceuticals’s earnings last quarter?
Xenon Pharmaceuticals released its earnings results on May 07, 2026. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.179 by $0.009.
Is Xenon Pharmaceuticals overvalued?
According to Wall Street analysts Xenon Pharmaceuticals’s price is currently Undervalued.
Does Xenon Pharmaceuticals pay dividends?
Xenon Pharmaceuticals does not currently pay dividends.
What is Xenon Pharmaceuticals’s EPS estimate?
Xenon Pharmaceuticals’s EPS estimate is -1.14.
How many shares outstanding does Xenon Pharmaceuticals have?
Xenon Pharmaceuticals has 96,665,550 shares outstanding.
What happened to Xenon Pharmaceuticals’s price movement after its last earnings report?
Xenon Pharmaceuticals reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.179. Following the earnings report the stock price went up 0.786%.
Which hedge fund is a major shareholder of Xenon Pharmaceuticals?
Currently, no hedge funds are holding shares in XENE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xenon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.88 (15.98% Upside)
$75.88 (15.98% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
86.58%
Trailing 12-Months
Company Description
Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
XENE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed overwhelmingly positive clinical and corporate momentum: a highly favorable XTOL-2 Phase 3 data set with strong efficacy, long-term seizure freedom signals, a consistent safety profile, and a fortified balance sheet ($1.3B) supporting operations into 2029. The company has a clear regulatory path (NDA guidance for 2026) and active commercial and payer engagement. Remaining uncertainties are largely execution and timing risks (regulatory scheduling, commercial launch logistics, payer access) and limited near-term public granularity on Phase 1 pain data. On balance, the highlights are substantial and materially outweigh the modest operational and timing risks discussed.View all XENE earnings summariesXENE Stock 12 Month Forecast
Average Price Target
$75.88
▲(15.98% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Scholar Rock Holding
―
Immunovant
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
0.13% Insiders
28.19% Mutual Funds
1.15% Other Institutional Investors
63.00% Public Companies and
Individual Investors